Q-omics provides the consensus-scored REEP6 profile across patient tissues and cancer cell-line models. REEP6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, REEP6 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, REEP6 protein abundance shows 15,631 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UCS, KIRC, and BRCA as cancer lineages where REEP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REEP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REEP6 survival associations across molecular data types. REEP6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REEP6 RNA expression–survival associations across cancer types. High REEP6 expression shows unfavorable associations in UCS, KIRC, MESO and SARC, but favorable associations in ACC and LGG. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for REEP6 RNA expression.
This table summarizes REEP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for REEP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REEP6 shows lower tumor expression in KIRC, KIRP, KICH and HNSC and higher tumor expression in COAD and LUAD. The KIRC box plot shows higher REEP6 RNA expression in normal versus tumor tissue (log2 FC = −2.835, t-test p < 0.001).
This table shows molecular features associated with REEP6 in patient tissues and cancer cell lines. In patient samples, REEP6 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, REEP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
